Business Wire

QPS Launches New Leukopak and Cell Therapy Products Facility

Share

QPS Holdings, LLC announced today that their Springfield campus, QPS Missouri, has launched a new Cell Therapy business unit. The unit’s first achievement is the opening of a new Leukopak collection and blood product processing center. This facility is designed to meet the exponentially growing demand for blood products to support cell and gene therapy work. QPS is a full service CRO that’s dedicated to supporting drug development from conceptualization through to commercial launch. This facility is providing critical raw materials for the research and development of cell therapies but will soon be supporting clinical and commercial cell therapy companies and patients. In addition, this new facility will support the local economy by providing stipends to blood product donors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241113328476/en/

The new QPS Cell Therapy Unit in Springfield, Missouri is a Leukopak collection and blood product processing center designed to meet the exponentially growing demand for blood products to support cell and gene therapy work. (Photo: Business Wire)

To build out the facility and ensure the success of this new venture, QPS has hired Tia Hexom, PhD, (Senior Director of Cell Therapy Services and Manufacturing). With over a decade of experience in the cell therapy field, Hexom is excited to be building cell therapy capabilities in the Midwestern United States.

QPS Missouri is a division of QPS Holdings LLC, a global Clinical Research Organization (CRO) that conducts studies on behalf of pharmaceutical and biotech companies for the development of new and existing pharmaceutical products. This new Leukopak and Cell Therapy products donation and processing center will be housed in the same building as the new, state-of-the-art Screening and Recruitment Center that opened in July 2022, located at 2025 W. Sunshine Street, Springfield, MO. Study participants and blood product donors are paid a stipend for their participation in these Clinical Research activities. These stipends benefit the study participants and donors and, therefore, the local economy.

“Our participants and donors are a key part of the success of QPS in Springfield, Missouri and they continue to make a difference by helping advance drug development research,” states Brendon Bourg, Vice President, Early Phase Clinical/Head of Administration QPS Missouri. “To have the opportunity and ability to provide this type of supplemental income to our local community, while providing a valuable service to our pharmaceutical and biotech clients is something we (QPS) are honored to be a part of.”

Located in Springfield, QPS Missouri has been conducting clinical research studies for over 30 years, with the help of more than 50,000 study participants. In addition to the new Cell Therapy facilities, the Springfield campus houses five independent clinics with more than 240 beds, a pharmacy with a retention area, local and central CAP/CLIA safety lab, a clinical trial kit processing area, and a 2,500 square foot negative pressure room.

QPS has always been on the front line of clinical research in all areas of pharmaceutical and biotech drug development. Since opening its doors in Springfield in 1994, QPS Missouri has conducted more than 2,000 Phase I FDA-regulated studies and paid over $50 million to local participants and donors.

ABOUT QPS HOLDINGS, LLC

QPS is a global, full-service, GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, bioanalysis, preclinical and clinical drug development services. Since 1995, QPS has grown from a small bioanalysis shop into a full-service CRO with 1,100+ employees in the US, Europe, and Asia. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, cell therapy products (such as Leukopaks and PBMCs), clinical trials, and clinical research services. An award-winning leader focused on bioanalysis and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, turnkey laboratories, Phase I clinical facilities, and multi-site clinical research services. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance, and trusted service to its valued customers. For more information, visit www.qps.com or email info@qps.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241113328476/en/

Contacts

Gabrielle Pastore, QPS Marketing
Phone: 302-287-7821
Email: gabrielle.pastore@qps.com
Website: www.qps.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.qps.com&esh
eet=54151703&newsitemid=20241113328476&lan=en-US&anchor=www.qps.com&index=2&md5=
8586b94df60fd6abd834882cd1e26b64

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SBC Medical Group Holdings Inc. Reports Third Quarter 2024 Financial Results13.11.2024 22:59:00 CET | Press Release

SBC Medical Group Holdings Incorporated (“SBC Medical”, or the “Company”), a global owner, operator and provider of management services and products to cosmetic treatment centers, today announced its unaudited financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Highlights Total revenues for the three months ended September 30, 2024 were $53 million, representing an increase of 12% from $47 million in the same quarter of 2023. Total revenues for the nine months ended September 30, 2024 was $160 million, representing an increase of 23% from $131 million in the same period of 2023. Income from operations for the three months ended September 30, 2024 was $13 million, representing a decrease by 31% from the same quarter in 2023. This result was impacted by $12.8 million of stock-based compensation expense related to the Company’s listing process. Income from operations for the nine months ended September 30, 2024 was $65.5 million, representing an increase o

Altasciences’ Commitment to Supporting Pharma and Biotech With Comprehensive Bioanalytical Services13.11.2024 18:00:00 CET | Press Release

Altasciences, a trusted drug development research partner for over 30 years, continues its commitment to providing world-class bioanalytical services. This core business supports both preclinical and clinical studies conducted at Altasciences’ facilities, while also offering an extensive standalone solution to meet the diverse needs of clients. By delivering high-quality, flexible bioanalytical services, Altasciences remains dedicated to advancing drug development and empowering clients across every phase of research. For three decades now, Altasciences has taken pride in evolving their solutions to meet the needs of pharmaceutical and biotechnology companies of all sizes, including the expansion of their labs in Seattle, WA, Columbia, MO, and Laval, Québec. Their three state-of-the-art bioanalytical laboratories feature mirrored operations and uniform protocols to maintain consistency and quality across client projects, ensuring reliable, high-quality data regardless of location. This

Medidata Secures Highest Leadership Position in Everest Group’s First Life Sciences Clinical Trial Management System Products PEAK Matrix ® Assessment13.11.2024 15:30:00 CET | Press Release

Medidata, a Dassault Systèmes brand and the leading provider of clinical trial solutions to the life sciences industry, has been recognized as a leader in Everest Group's first-ever Life Sciences Clinical Trial Management System Products PEAK Matrix® Assessment 2024. The report assessed 13 providers based on the market impact of their products and their ability to deliver successful, high-quality offerings. Medidata Rave CTMS leads the industry by providing seamless, real-time patient data outputs that transform enrollment tracking and enable faster, data-driven decisions. Offering instant visibility for study teams, Rave CTMS streamlines collaboration, eliminates manual data entry, and accelerates trial timelines with exceptional accuracy. “We are honored to be recognized as the highest leader in CTMS by Everest Group,” said Tom Doyle, chief technology officer, Medidata. “This accolade underscores our unwavering commitment to transforming research and reaffirms our strategy to deliver

China Moutai Showcases Ecology Promotion Practices at the China Pavilion During COP2913.11.2024 15:05:00 CET | Press Release

At a side event titled "Ecological Civilization and Beautiful China Practices" during the 2024 UN Climate Change Conference (COP29) in Baku, Azerbaijan, China Moutai showcased its commitment to ecological sustainability and called for greater attention to climate change. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241113718721/en/ Li Wang, General Manager of China Moutai Group, presented at the side event in Baku. (Photo: Business Wire) Li Wang, General Manager of China Moutai Group, emphasized that Chinese modernization is rooted in achieving harmony between humanity and nature. She said that as a representative of China’s liquor industry, Moutai has embraced the principle that "lucid waters and lush mountains are invaluable assets." This philosophy underscores the company’s approach to modernization, which prioritizes environmental stewardship. Wang highlighted Moutai Group’s dedication to leveraging regional ecological

Andersen Global Adds M&A and Investment Banking Capabilities to Platform in South Africa13.11.2024 15:00:00 CET | Press Release

Andersen Global continues to build its multidisciplinary platform in South Africa through a Collaboration Agreement with Merchantec Capital, an M&A and investment banking firm based in Johannesburg. Operating for over two decades, Merchantec Capital offers a diverse range of services, including mergers and acquisitions advisory, valuations, equity and debt capital raising services, corporate governance, JSE equity and debt sponsor services, research, and wealth management. The firm works with public companies, large corporations, privately-owned businesses, management teams, and private equity firms, providing strategic solutions that meet both local and international business needs. “Providing objective, one-stop solutions for clients has been a key objective and driving force behind our growth to date,” shared Executive Director Marcel Goncalves. “This collaboration with Andersen Global enables us to continue to serve clients objectively and expands our reach to assist clients with c

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye